Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Nature Genetics|January 15, 2013
Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanomaJ William Harbour, Elisha D O Roberson, Hima Anbunathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanomaLori A Worley, Michael D Onken, Erica Person, et al.
Investigative Ophthalmology & Visual Science|August 23, 2008
Oncogenic mutations in GNAQ occur early in uveal melanomaMichael D Onken, Lori A Worley, Meghan D Long, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 27, 2019
Diabetes self-management education exposure and glycated haemoglobin levels among Marshallese participants in a randomized controlled studyP A McElfish, C R Long, Z Bursac, et al.
Frontiers in Molecular Biosciences|November 29, 2023
Use of AgomiR and AntagomiR technologies to alter satellite cell proliferation <i>in vitro</i>, miRNA expression, and muscle fiber hypertrophy in intrauterine growth-restricted lambsM A Greene, G A Worley, A N S Udoka, et al.
Journal of Autism and Developmental Disorders|July 10, 2017
Amygdala Volume Differences in Autism Spectrum Disorder Are Related to AnxietyJohn D Herrington, Brenna B Maddox, Connor M Kerns, et al.
Science (New York, N.Y.)|November 6, 2010
Frequent mutation of BAP1 in metastasizing uveal melanomasJ William Harbour, Michael D Onken, Elisha D O Roberson, et al.
Cancer Immunology, Immunotherapy : CII|March 22, 2014
Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancerRoheena Z Panni, Dominic E Sanford, Brian A Belt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2013
Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axisDominic E Sanford, Brian A Belt, Roheena Z Panni, et al.
The Lancet. Oncology|April 9, 2016
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trialTimothy M Nywening, Andrea Wang-Gillam, Dominic E Sanford, et al.
Pageof 8